Good morning! Cosmetic eyelid surgery is rising fastest among people 25 and under. Also today: 311 UK reports of deaths linked to GLP-1 drugs, Deloitte's US health plans dropping GLP-1 weight loss coverage, and Sunnyside's semaglutide with naltrexone for heavy drinking. Listen to me read them above, or read the key details below.
Daily Roundup:
Cosmetic eyelid surgery is rising fastest among people 25 and under (The Independent)
UK reports of deaths linked to GLP-1 drugs have reached 311, with the most among people in their 60s (Daily Mail)
Deloitte's US health plans will drop GLP-1 coverage for weight loss (Business Insider)
Sunnyside now offers semaglutide with naltrexone for heavy drinking (PR Newswire)
Cosmetic eyelid surgery is rising fastest among people 25 and under
Key Details:
About 119,000 of these surgeries were done in the U.S. in 2025, up 19 percent from 2024, the American Society of Plastic Surgeons says.
Fewer young adults have the surgery than people over 45, but their yearly rise was the biggest.
The article says the increase has been traced to social media, celebrities and GLP-1 drugs, which can cause a sunken look called "Ozempic face."
The outpatient procedure costs 3,000 dollars, and insurance covers it only when drooping skin blocks vision.
Source: The Independent
UK reports of deaths linked to GLP-1 drugs have reached 311, with the most among people in their 60s
Key Details:
The count comes from the Yellow Card scheme run by the MHRA, the UK medicines regulator, and is up from 216 in August.
The reports do not show the drugs caused the deaths, only that someone suspected they may have played a role.
There were 88 reported deaths among people in their 60s and 20 among people in their 40s, even though people in their 40s are about three and a half times more likely to be prescribed the drugs.
Dr Alex Miras of Imperial College London said, "People in older age groups have a higher chance of dying anyway."
Source: Daily Mail
Deloitte's US health plans will drop GLP-1 coverage for weight loss
Key Details:
The change is in an internal benefits guide seen by the outlet, and the drugs stay covered for diabetes and other covered conditions.
For weight loss, the firm will offer a virtual program called eMed, with coaching and a 125 dollar employer contribution per prescription.
Most plans will also have higher deductibles and out-of-pocket maximums.
The firm, which employs about 181,000 people in the US, told staff the changes "reflect the hard trade-offs of today's cost environment."
Source: Business Insider
Sunnyside now offers semaglutide with naltrexone for heavy drinking
Key Details:
The company launched two programs on November 12, at 199 dollars a month for a microdose and 299 dollars a month for a full dose, plus a one-time 50 dollar intake fee.
Naltrexone has been FDA-approved for alcohol dependence since 1994, but semaglutide is not FDA-approved to treat alcohol use disorder.
The medications are compounded, and the release notes the FDA does not review compounded drugs for safety, effectiveness or quality.
CEO Nick Allen said, "It's clear that medication can quiet the urge to drink in the moment, but it won't change the ingrained habits around drinking on its own."
Source: PR Newswire
Learn More
Join the free GLP-1 community Cozy Butter: cozybutter.com
Listen to GLP-1 Radio, GLP-1 shows all day: glp1radio.com
Every GLP-1 Studio Daily episode: GLP-1 Studio Daily
About Amanda Bonello: amandabonello.com
This is a reader-supported publication, thank you so much for your support.
💖












